Yongge Liu

List of Publications by Year in descending order

36 papers	4,267 citations	172207 29 h-index	344852 36 g-index
36 all docs	36 docs citations	36 times ranked	3324 citing authors

#	Article	IF	Citations
1	Mitochondrial ATP-Dependent Potassium Channels. Circulation, 1998, 97, 2463-2469.	1.6	781
2	Cytoprotective Role of Ca2+- Activated K+ Channels in the Cardiac Inner Mitochondrial Membrane. Science, 2002, 298, 1029-1033.	6.0	445
3	Role of Bradykinin in Protection of Ischemic Preconditioning in Rabbit Hearts. Circulation Research, 1995, 77, 611-621.	2.0	441
4	Evidence that Translocation of Protein Kinase C is a Key Event During Ischemic Preconditioning of Rabbit Myocardium. Journal of Molecular and Cellular Cardiology, 1994, 26, 661-668.	0.9	298
5	Cilostazol (PletalÂ®): A Dual Inhibitor of Cyclic Nucleotide Phosphodiesterase Type 3 and Adenosine Uptake. Cardiovascular Drug Reviews, 2001, 19, 369-386.	4.4	172
6	Cilostazol as a Unique Antithrombotic Agent. Current Pharmaceutical Design, 2003, 9, 2289-2302.	0.9	166
7	Synergistic Modulation of ATP-Sensitive K + Currents by Protein Kinase C and Adenosine. Circulation Research, 1996, 78, 443-454.	2.0	144
8	Mitochondrial ATP-Dependent Potassium Channels: Viable Candidate Effectors of Ischemic Preconditioninga. Annals of the New York Academy of Sciences, 1999, 874, 27-37.	1.8	137
9	Intrinsic Myofilament Alterations Underlying the Decreased Contractility of Stunned Myocardium. Circulation Research, 1996, 78, 455-465.	2.0	134
10	Platelet P2Y₁₂ Blockers Confer Direct Postconditioning-Like Protection in Reperfused Rabbit Hearts. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 251-262.	1.0	133
11	Selective Effects of Oxygen Free Radicals on Excitation-Contraction Coupling in Ventricular Muscle. Circulation, 1996, 94, 2597-2604.	1.6	125
12	Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1receptor activation. Journal of the American College of Cardiology, 2000, 35, 238-245.	1.2	104
13	Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis, 2018, 108, 186-194.	0.8	103
14	Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells. Journal of Cardiovascular Pharmacology, 1999, 34, 497-504.	0.8	103
15	Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis, 2018, 111, 20-30.	0.8	101
16	Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cellular Signalling, 2007, 19, 1765-1771.	1.7	91
17	Phospholipase D Plays a Role in Ischemic Preconditioning in Rabbit Heart. Circulation, 1996, 94, 1713-1718.	1.6	84
18	Chelerythrine, a highly selective protein kinase C inhibitor, blocks the antiinfarct effect of ischemic preconditioning in rabbit hearts. Cardiovascular Drugs and Therapy, 1994, 8, 881-882.	1.3	67

#	Article	IF	Citations
19	Inhibition of Adenosine Uptake and Augmentation of Ischemia-Induced Increase of Interstitial Adenosine by Cilostazol, an Agent to Treat Intermittent Claudication. Journal of Cardiovascular Pharmacology, 2000, 36, 351-360.	0.8	62
20	Two Classes of Anti-Platelet Drugs Reduce Anatomical Infarct Size in Monkey Hearts. Cardiovascular Drugs and Therapy, 2013, 27, 109-115.	1.3	61
21	The Fab Fragment of a Novel Anti-GPVI Monoclonal Antibody, OM4, Reduces In Vivo Thrombosis Without Bleeding Risk in Rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1199-1205.	1.1	60
22	Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovascular Drugs and Therapy, 2002, 16, 417-427.	1.3	59
23	Mitochondrial ATP-sensitive K+channels play a role in cardioprotection by Na+-H+exchange inhibition against ischemia/reperfusion injury. Journal of the American College of Cardiology, 2001, 37, 957-963.	1.2	56
24	MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration. Antimicrobial Agents and Chemotherapy, 2016, 60, 3316-3322.	1.4	49
25	New Mechanism of Action for Cilostazol: Interplay Between Adenosine and Cilostazol in Inhibiting Platelet Activation. Journal of Cardiovascular Pharmacology, 2002, 40, 577-585.	0.8	42
26	Attenuation of infarction in cynomolgus monkeys: preconditioning and postconditioning. Basic Research in Cardiology, 2010, 105, 119-128.	2.5	37
27	Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. Platelets, 2004, 15, 167-172.	1.1	36
28	Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts. PLoS Medicine, 2019, 16, e1002780.	3.9	36
29	Interplay Between Inhibition of Adenosine Uptake and Phosphodiesterase Type 3 on Cardiac Function by Cilostazol, an Agent to Treat Intermittent Claudication. Journal of Cardiovascular Pharmacology, 2001, 38, 775-783.	0.8	34
30	Opening of Mitochondrial K ATP Channels Triggers Cardioprotection. Circulation Research, 2001, 88, 750-752.	2.0	30
31	Suppression of K ATP currents by gene transfer of a dominant negative Kir6.2 construct. Pflugers Archiv European Journal of Physiology, 1998, 436, 957-961.	1.3	17
32	Cilostazol and Dipyridamole Synergistically Inhibit Human Platelet Aggregation. Journal of Cardiovascular Pharmacology, 2004, 44, 266-273.	0.8	17
33	Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	13
34	Antiplatelet and Antithrombotic Activity of Cilostazol is Potentiated by Dipyridamole in Rabbits and Dissociated from Bleeding Time Prolongation. Cardiovascular Drugs and Therapy, 2005, 19, 41-48.	1.3	11
35	Cilostazol Increases Tissue Blood Flow in Contracting Rabbit Gastrocnemius Muscle. Circulation Journal, 2010, 74, 181-187.	0.7	11
36	Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts. BMC Infectious Diseases, 2022, 22, 327.	1.3	7